On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Pius Hospital Oldenburg

InstitutionResearch output, impact & collaborations

Pius Hospital Oldenburg is a institution indexed in ScholarIQ from OpenAlex.

What is known about Pius Hospital Oldenburg?

ScholarIQrecord summary

Pius Hospital Oldenburg is a research organisation in Oldenburg, DE. OpenAlex records 1,492 works and 60,948 citations for it. 332 researchers list it as their most recent affiliation.

How many works does Pius Hospital Oldenburg have?

ScholarIQindexed works

Pius Hospital Oldenburg has 1,492 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Pius Hospital Oldenburg have?

ScholarIQcitation count

Pius Hospital Oldenburg has 60,948 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at Pius Hospital Oldenburg?

ScholarIQresearcher count

Pius Hospital Oldenburg has 332 researchers in the ScholarIQ index.

What is the average h-index at Pius Hospital Oldenburg?

ScholarIQavg h-index

Pius Hospital Oldenburg has an average h-index of 56 in OpenAlex.

What is the ROR of Pius Hospital Oldenburg?

ScholarIQror

The ROR for Pius Hospital Oldenburg is on the source record.

What is the OpenAlex record for Pius Hospital Oldenburg?

ScholarIQopenalex

The OpenAlex for Pius Hospital Oldenburg is on the source record.

Who are the most-cited researchers behind Pius Hospital Oldenburg?

ScholarIQtop researchers by citations
1
Frank Griesinger · Lung Cancer Treatments and Mutations
604 works14,799 citations

What are the most-cited papers on Pius Hospital Oldenburg?

ScholarIQmost cited works
Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease
JJM van Dongen, EA Macintyre, J Gäbert, Éric Delabesse, V Rossi, Giuseppe Saglio, Enrico Gottardi, Alessandro Rambaldi, Gianpietro Dotti, Frank Griesinger, A Parreira, Paula Gameiro, M González Diáz, M Malec, A W Langerak, Jesús F. San Miguel, Andrea Biondi
Leukemia. 19991,166 Citations
Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer
D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Jong Seok Lee, Maximilian J. Hochmair, Jacky Yu-Chung Li, Gee‐Chen Chang, Ki Hyeong Lee, Cesare Gridelli, Angelo Delmonte, Rosario García Campelo, Dong‐Wan Kim, Alessandra Bearz, Frank Griesinger, Alessandro Morabito, Enriqueta Felip, Raffaele Califano, Sharmistha Ghosh, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Neeraj Gupta, J. Haney, David Kerstein, Sanjay Popat
New England Journal of Medicine. 2018987 CitationsOPEN ACCESS
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
Paul K. Paik, Enriqueta Felip, Rémi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina Chiara Garassino, Julien Mazières, Santiago Viteri, Hélène Senellart, Jan P. van Meerbeeck, Jo Raskin, Niels Reinmuth, PierFranco Conte, Dariusz M. Kowalski, Byoung Chul Cho, Jyoti D. Patel, Leora Horn, Frank Griesinger, Ji‐Youn Han, Young‐Chul Kim, Gee‐Chen Chang, Chen‐Liang Tsai, James Chih‐Hsin Yang, Yuh-Min Chen, Egbert F. Smit, Anthonie J. van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, John V. Heymach, Xiuning Le
New England Journal of Medicine. 2020872 CitationsOPEN ACCESS
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Eckhard Thiel, Agnieszka Korfel, Peter Martus, Lothar Kanz, Frank Griesinger, Michael Rauch, Alexander Röth, Bernd Hertenstein, Theda von Toll, Thomas Hundsberger, H.‐G. Mergenthaler, Malte Leithäuser, Tobias Birnbaum, Lars Fischer, Kristoph Jahnke, Ulrich Herrlinger, Ludwig Plaßwilm, Thomas Nägele, Torsten Pietsch, Michael Bamberg, Michael Weller
The Lancet Oncology. 2010623 Citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gϋnter von Minckwitz, Stephen Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Z. Tomasevic, Neelima Denduluri, Robert Šeparović, Erhan Gökmen, Anna Bashford, Manuel Ruíz Borrego, Sung‐Bae Kim, Erik Jakobsen, A. Ciceniene, Kenichi Inoue, Friedrich Overkamp, Joan B. Heijns, Anne Armstrong, John S. Link, Anil A. Joy, Richard Bryce, Alvin Wong, Susan Moran, Bin Yao, Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan, Vernon Harvey, Rudolf Tomek, Nicholas J. Robert, Ira Gore, John W. Smith, Norikazu Masuda, S. Di Sean Kendall, William Graydon Harker, Katarína Petráková, Ángel Guerrero‐Zotano, Amparo Ruiz Simón, Zora Neskovic Konstantinovic, Nicholas Iannotti, Pierfrancesco Tassone, Gladys Rodriguez, Noelia Jáñez Martínez, Carmen Crespo Massieu, Snezana Smickoska, Işıl Somali, Uğur Yılmaz, Mirta Garcia Alonso, Adolfo Rosales, Soeren Cold, Ann Knoop, Debra A. Patt, Beth A. Hellerstedt, Serafin Morales Murillo, Ingrid A. Mayer, Julie A. Means‐Powell, Rina Hui, Francis M. Senecal, Richard Hendry De Boer, Zhenzhou Shen, A.A. Luczak, Joanna W.Y. Chui, Janice Tsang, István Láng, Yoshiaki Rai, Yasuo Hozumi, Albert J. ten Tije, Manish Bhandari, Cynthia R. Osborne, Shoichiro Ohtani, Kenji Higaki, Kenichi Watanabe, Kazunori TAGUCHI, Masato Takahashi, Sladjana Filipovic, Vincent Hansen, Vijayarama Phooshkooru Rao, Manish Gupta, Petar Petrov, Bruno Coudert, Željko Vojnović, Zsofia Polya, Toshiko Miyaki, Naohito Yamamoto, Stephen Brincat, Krzysztof Leśniewski-Kmak, Ewa Chmielowska, Ruemu Birhiray, Marc L. Citron, Steven W. Papish, William L. Berry, Sven Tyge Langkjer, José Á. García-Sáenz
The Lancet Oncology. 2017593 Citations

How much of the research on Pius Hospital Oldenburg is open access?

ScholarIQopen access share
67%OPEN ACCESS
Gold
0%
Green
8%
Hybrid
25%
Bronze
33%
Closed
33%

Related on ScholarIQ

470M+ articles · 14-day free trial